Post by
MrMugsy on Nov 19, 2022 6:54pm
Thanks for all your comments guys ...
So many unknowns but I do see some potential connections between our present and future drugs.
Not sure where our use of nano fits - might be sooner than later or it might be well in the future - can't really tell at this point.
With the latest modification in OTENA formulation, I see Acute Pain growing in size ...
- pre-op
- intra-op
- post-op
Focus on getting post-op first and growing it out completely.
The formula has us staring at a much reduced chronic daily - so - we don't know yet if we can fly under the liver's radar. What we do know is ... getting to a chronic solution should be easier now than ever before.
Then we have IBD
- Crohn's
- Colitis
- IBS (maybe with improved microbiome and more H2S2 will get the softness/hardness of the stool just right - especially with all the ultraprocessed foods we eat)
- chronic intestinal inflammation
Maybe that's where you can look for potential colon cancer - certain chronic intestinal inflammation ???? Regardless, good thing we have OTENA ... could help reduce/reverse colon cancer in the future. That's what we're seeing in animal models. But, focus on acute/chronic. The potential for cancer can be investigated later on.
So what about autoimmune diseases like IBD ?
"With an autoimmune disease, a person's own immune system attacks the lungs, causing inflammation and scarring that can impair lung function and breathing"
- Asthma
- Chronic Broncitis
- COPD
etc ...
What do we have on the respiratory side? The antiviral (our Indomethacin based drug). Maybe an Antiviral/IBD combo for all we know. Is that why we have the Antiviral IP waiting in the wings ?
There's how I see the connections right now.
------------------------------
Finally, what is Wallace working on? Is he still on IBD or is he working with the Antiviral and/or some combinations thereof? If I were to bet, I'd say some combination(s).
What comes after those drugs? Then we're into neuro-inflammation.
I'm going to assume we're certainly not there yet - but - I'm sure Wallace is eventually going to be looking at getting our drugs (as needed) past the blood/brain barrier and into areas of neuro-inflammation. Lots of H2S3 potential in the brain I would think.
H2S - in general - used to develop polysulfides in the body ?????
H2S2 - healthy gut ?????
H2S3 - healthy brain ?????
Just throwing out some ideas - I honestly haven't a clue - but the puzzle pieces are there. The question just becomes, how do they fit ?
I tell Dan he's a hydrogen polysulfides company and he tells me ATE is a "targeting inflammation" company. Who knows ... maybe we're talking about the same thing ... maybe we're not.
Fact is - everything at ATE will be done under a veil of secrecy and there's just no way around that. Without secrecy there's no value to the IP. Without IP, first-to-market isn't an advantage.
Tough game - but - it's obvious they are up to the challenge. That's why I'm here as an investor.
2023 seems to be all about getting our first drug into negotiations and hopefully on both the acute and chronic sides. There's a reason for picking the modified formulation for OTENA ... to get the biggest possible bang for future OTENA negotiations.
What would Dan say ? We only get one chance to do it ... so let's do it right.
That's right ... the issues with chronic isn't a failure ... as far as I'm concerned, it's part of the process in OTENA drug development.
If the modified formula wins - if it's the biggest risk-reduced bang for the development dollar - then so be it. We follow the modified formulation.
BINGO - BANGO - BONGO !
P.S. ... Dan wouldn't say that last part - I'm sure. That's all me. : )